NCT05315180

A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

A Phase 1，Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-421286 in Subjects With Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Betta Pharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.

Conditions

• Malignant Neoplasms
• Metastatic Cancer

Interventions

Type	Name	Description
DRUG	BPI-421286	Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation

Timeline

• Start date: 2021-08-24
• Primary completion: 2023-07-31
• Completion: 2023-07-31
• First posted: 2022-04-07
• Last updated: 2022-04-07

Locations

5 sites across 1 country: China